Bicycle Therapeutics (NASDAQ:BCYC) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Bicycle Therapeutics and provided 12-month price targets. The average target is $22.0, accompanied by a high estimate of $32.00 and a low estimate of $14.00. Observing a downward trend, the current average is 20.61% lower than the prior average price target of $27.71.

Deciphering Analyst Ratings: An In-Depth Analysis

A clear picture of Bicycle Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bicycle Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Bicycle Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Bicycle Therapeutics: A Closer Look

Bicycle Therapeutics's Economic Impact: An Analysis

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Negative Revenue Trend: Examining Bicycle Therapeutics's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -48.91% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Bicycle Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -608.94%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Bicycle Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.92% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Bicycle Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -6.6%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Bicycle Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.